Dong-A St (170900) - Net Assets
Based on the latest financial reports, Dong-A St (170900) has net assets worth ₩671.65 Billion KRW (≈ $455.17 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.41 Trillion ≈ $956.92 Million USD) and total liabilities (₩740.40 Billion ≈ $501.76 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Dong-A St to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩671.65 Billion |
| % of Total Assets | 47.57% |
| Annual Growth Rate | 3.6% |
| 5-Year Change | 2.33% |
| 10-Year Change | 13.99% |
| Growth Volatility | 5.65 |
Dong-A St - Net Assets Trend (2013–2025)
This chart illustrates how Dong-A St's net assets have evolved over time, based on quarterly financial data. See Dong-A St (170900) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Dong-A St (2013–2025)
The table below shows the annual net assets of Dong-A St from 2013 to 2025. For live valuation and market cap data, see Dong-A St market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩671.65 Billion ≈ $455.17 Million |
-5.24% |
| 2024-12-31 | ₩708.81 Billion ≈ $480.35 Million |
+3.73% |
| 2023-12-31 | ₩683.31 Billion ≈ $463.07 Million |
-0.99% |
| 2022-12-31 | ₩690.11 Billion ≈ $467.68 Million |
+5.14% |
| 2021-12-31 | ₩656.38 Billion ≈ $444.82 Million |
+2.22% |
| 2020-12-31 | ₩642.10 Billion ≈ $435.14 Million |
-0.58% |
| 2019-12-31 | ₩645.86 Billion ≈ $437.69 Million |
+11.48% |
| 2018-12-31 | ₩579.36 Billion ≈ $392.63 Million |
-0.31% |
| 2017-12-31 | ₩581.19 Billion ≈ $393.87 Million |
-1.36% |
| 2016-12-31 | ₩589.22 Billion ≈ $399.31 Million |
+6.40% |
| 2015-12-31 | ₩553.77 Billion ≈ $375.28 Million |
+13.40% |
| 2014-12-31 | ₩488.34 Billion ≈ $330.94 Million |
+11.15% |
| 2013-12-31 | ₩439.36 Billion ≈ $297.75 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Dong-A St's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 21139292240000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩151.67 Billion | 23.60% |
| Other Components | ₩491.04 Billion | 76.40% |
| Total Equity | ₩642.71 Billion | 100.00% |
Dong-A St Competitors by Market Cap
The table below lists competitors of Dong-A St ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CHTC Helon Co Ltd
SHE:000677
|
$238.95 Million |
|
Webzen Inc
KQ:069080
|
$239.15 Million |
|
Asure Software Inc
NASDAQ:ASUR
|
$239.20 Million |
|
Sunrex Technology Corp
TW:2387
|
$239.31 Million |
|
Huuuge Inc.
WAR:HUG
|
$238.81 Million |
|
Universal Microelectronics Co Ltd
TW:2413
|
$238.74 Million |
|
Cathay Chemical Works Inc
TW:1713
|
$238.74 Million |
|
Tiansheng Pharmaceutical Group Co Ltd
SHE:002872
|
$238.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dong-A St's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 670,285,789,000 to 642,711,048,000, a change of -27,574,741,000 (-4.1%).
- Net loss of 28,592,457,000 reduced equity.
- Dividend payments of 6,288,477,300 reduced retained earnings.
- Share repurchases of 206,524,380 reduced equity.
- New share issuances of 8,452,866,860 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-28.59 Billion | -4.45% |
| Dividends Paid | ₩6.29 Billion | -0.98% |
| Share Repurchases | ₩206.52 Million | -0.03% |
| Share Issuances | ₩8.45 Billion | +1.32% |
| Other Changes | ₩-940.15 Million | -0.15% |
| Total Change | ₩- | -4.11% |
Book Value vs Market Value Analysis
This analysis compares Dong-A St's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.55x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩68874.87 | ₩36550.00 | x |
| 2018-12-31 | ₩68658.01 | ₩36550.00 | x |
| 2019-12-31 | ₩76538.02 | ₩36550.00 | x |
| 2020-12-31 | ₩76092.34 | ₩36550.00 | x |
| 2021-12-31 | ₩77781.70 | ₩36550.00 | x |
| 2022-12-31 | ₩73133.33 | ₩36550.00 | x |
| 2023-12-31 | ₩76450.29 | ₩36550.00 | x |
| 2024-12-31 | ₩73113.84 | ₩36550.00 | x |
| 2025-12-31 | ₩66800.37 | ₩36550.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dong-A St utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3.54%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 2.20x
- Recent ROE (-4.45%) is below the historical average (1.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -17.97% | -15.74% | 0.54x | 2.12x | ₩-122.74 Billion |
| 2014 | 7.67% | 6.47% | 0.53x | 2.22x | ₩-11.39 Billion |
| 2015 | 8.77% | 8.55% | 0.53x | 1.92x | ₩-6.80 Billion |
| 2016 | 1.80% | 1.90% | 0.53x | 1.81x | ₩-48.29 Billion |
| 2017 | -0.93% | -0.97% | 0.62x | 1.55x | ₩-63.51 Billion |
| 2018 | 1.38% | 1.41% | 0.60x | 1.64x | ₩-49.93 Billion |
| 2019 | 10.98% | 11.58% | 0.61x | 1.56x | ₩6.33 Billion |
| 2020 | 4.22% | 4.62% | 0.60x | 1.53x | ₩-37.11 Billion |
| 2021 | 1.95% | 2.16% | 0.53x | 1.70x | ₩-52.82 Billion |
| 2022 | 2.02% | 2.13% | 0.55x | 1.72x | ₩-53.61 Billion |
| 2023 | 1.69% | 1.68% | 0.53x | 1.92x | ₩-54.61 Billion |
| 2024 | -0.18% | -0.18% | 0.50x | 2.08x | ₩-68.25 Billion |
| 2025 | -4.45% | -3.54% | 0.57x | 2.20x | ₩-92.86 Billion |
Industry Comparison
This section compares Dong-A St's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $623,217,776,252
- Average return on equity (ROE) among peers: 2.44%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dong-A St (170900) | ₩671.65 Billion | -17.97% | 1.10x | $238.87 Million |
| Dongwha Pharm.Co.Ltd (000020) | $401.44 Billion | 2.16% | 0.60x | $100.87 Million |
| Yuhan Corp. (000100) | $2.01 Trillion | 4.74% | 0.23x | $3.91 Billion |
| Yuhan Corp Preferred (000105) | $2.15 Trillion | 3.29% | 0.37x | $52.61 Million |
| Yuyu Pharma (000220) | $123.37 Billion | -4.85% | 0.58x | $42.66 Million |
| Yuyu Pharma Inc (000225) | $128.69 Billion | -1.72% | 0.50x | $15.37 Million |
| Yuyu Pharma Inc (000227) | $123.37 Billion | -4.85% | 0.58x | $42.45 Million |
| Ildong Holdings Co Ltd (000230) | $349.98 Billion | 5.99% | 1.02x | $56.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $104.16 Million |
| Donga Socio Holdings (000640) | $514.60 Billion | 3.03% | 0.92x | $374.79 Million |
| Jw Pharmac (001060) | $369.37 Billion | 16.65% | 0.64x | $416.42 Million |
About Dong-A St
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bl… Read more